Proactive Investors - Run By Investors For Investors

Immunoprecise Antibodies reports 2Q revenue doubled on increased capacity, European expansion

Highlights for the company included the purchases of U-Protein Express and ModiQuest Research
An illustration of antibodies
The antibodies developer cited an 'impressive increase' in the scale of services requested by prospects and clients

Immunoprecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) said its quarterly revenue doubled as the company increased capacity and expanded market share in Europe.

The Victoria, British Columbia-based biotech said late Monday in a press release that it increased high-margin projects at its B-cell lab and expanded in Europe by acquiring U-Protein Express and ModiQuest Research.

READ: Immunoprecise Antibodies adds new platforms to its range of services

For the second quarter ended October 31, the company reported that revenue climbed to C$2.7 million from C$1.3 million a year earlier. The net loss widened to C$1.5 million from C$903,000 as a result of additional staffing for projects.

“There has been an impressive increase in the scale of services requested by prospects and clients, further confirming the value of investing in our global presence,” Dr Jennifer Bath, CEO and president of Immunoprecise, said in a statement. "We are happy with our second-quarter performance.”

Immunoprecise reported that its gross margin increased to 52% from 41% and expects it to stay above 50% for the rest of fiscal 2019. As of October 31, the company said it had cash on hand of C$8.8 million and working capital of almost C$8.2 million.

Shares of the company fetched C$0.71 in Monday’s Canadian trading. They slipped US$0.01 to US$0.51 on the OTC Markets.

In late December, the company announced that Jason Orloske had accepted the position of vice president of operations for the company's global division.



Contact Dennis Fitzgerald at [email protected]

 

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

pills
Tue
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use